ALX Oncology Holdings - ALXO Net earnings per share for the last four quarters

Official company branding of ALX Oncology (ALXO)

The prospects for ALX Oncology Holdings (ALXO) are driven by the progress of evorpacept trials and the potential for acquisition by industry behemoths. Price action on GURU.Markets confirms this, showing an EPS of 56.10. A team of top-tier biologists is driving innovation under conditions of complete creative freedom. Meanwhile, the patent protection of the unique protein creates a temporary advantage, the success of which depends on the final stages of testing.

ALX Oncology Holdings (ALXO) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

ALXO (ALX Oncology): analytical breakdowns and indicator data

Initial company analysis:ALXO, ALX Oncology Holdings
Mass-produced product of alxoncology.com

In fundamental asset screening, earnings per share dynamics serve as a key indicator of business capitalization efficiency. By analyzing the history of EPS YoY (ttm) percentage changes, an investor assesses the annual growth rate of net income, which for ALX Oncology Holdings (ALXO) reflects the success of diversifying clinical programs and partnerships with pharma behemoths that mitigate regulatory risks in the development of oncology drugs.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months